Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

View:
Post by lonc17 on Nov 05, 2022 1:39pm

Monday

Things to think about before Monday morning. 

A look on clincialtrials shows 245 cancer studies presently recruiting or active:

https://clinicaltrials.gov/ct2/results?cond=Cancer&term=&type=&rslt=&recrs=a&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=DE&state=&city=hamburg&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=

A look at Dirk Arnolds linkedin shows hiim describing Goblet as one of AIO's "major trials"
https://it.linkedin.com/posts/dirk-arnold-7482a178_goblet-a-phase-iii-study-of-pelareorep-activity-6956625803358916608-v5VF?trk=public_profile_like_view

And it is interesting to see former Medical Officer Rita Laeufle reminding everyone that she designed the Goblet trial:
https://it.linkedin.com/posts/dirk-arnold-7482a178_oncolytics-activity-6990895915318321152-dxlj
Comment by lonc17 on Nov 05, 2022 1:41pm
Things to think about before Monday morning.  A look on clincialtrials shows 245 cancer studies presently recruiting or active: edit.. (in Hambburg...location of Goblet) https://clinicaltrials.gov/ct2/results?cond=Cancer&term=&type=&rslt=&recrs=a&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=DE&state=&city=hamburg& ...more  
Comment by westcoast1000 on Nov 05, 2022 2:45pm
Thanks for these interesting links, Ionc17.
Comment by westcoast1000 on Nov 05, 2022 3:22pm
Here is some useful , plain language information  about Goblet drawn from Ionc's links below: Abstract Most gastrointestinal (GI) cancers have microsatellite-stable (MSS) tumors, which have an immunologically ‘cold’ phenotype with fewer genetic mutations, reduced immune cell infiltration and downregulated immune checkpoint proteins. These attributes make MSS tumors ...more  
Comment by Noteable on Nov 05, 2022 4:11pm
Link to the Dirk paper .. https://www.futuremedicine.com/doi/10.2217/fon-2022-0453#.YtwNt7Ntolw.linkedin GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers Maike Collienne  ,  Houra Loghmani ,  Thomas Charles Heineman  &  Dirk Arnold
Comment by Noteable on Nov 05, 2022 4:17pm
Should read Dirk Arnold paper ...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities